Skip to main content
. Author manuscript; available in PMC: 2015 Apr 27.
Published in final edited form as: J Natl Cancer Inst. 2008 May 27;100(11):784–795. doi: 10.1093/jnci/djn157

Figure 1.

Figure 1

p16 and ARF expression in melanoma cell lines. A) Lysates from melanoma cell lines were subject to electrophoresis, and separated proteins were transferred to nitrocellulose membranes and probed with antibodies to p14ARF (ARF) (top) and p16INK4a (bottom). Blots were also probed with an antibody to the Ran protein as a control for equal loading and transfer. HeLa cells were used as a positive control for the expression of both ARF and p16. B) Treatment of SK-MEL 192 cells with the demethylating agent zebularine (Z). HeLa cells (underloaded due to the high expression of p14 ARF, lane 1) were used as a positive control. Lanes 2–6 were loaded with lysates prepared from SK-MEL 192 cells. Lane 2, no Z; lanes 3 and 4, after treatment with 0.1 mM Z for 24 hours (lane 3) or 96 hours (lane 4); lanes 5 and 6, after treatment with 0.4 mM Z for 24 hours (lane 5) or 96 hours (lane 6). Note the absence of p14ARF expression after 96 hours of treatment with a low dose of zebularine, compared with the sustained expression seen using the higher dose.